HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+7.61%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$175M
AUM Growth
+$175M
(+5.7%)
Cap. Flow
+$6.43M
Cap. Flow
% of AUM
3.67%
Top 10 Holdings %
Top 10 Hldgs %
36.64%
Holding
129
New
19
Increased
30
Reduced
20
Closed
16
Top Buys
| 1 |
NLSN
Nielsen Holdings plc
NLSN
|
$3.17M |
| 2 |
BKI
Black Knight, Inc. Common Stock
BKI
|
$2.73M |
| 3 |
VMW
VMware, Inc
VMW
|
$2.51M |
| 4 |
Repare Therapeutics
RPTX
|
$1.84M |
| 5 |
Cogent Biosciences
COGT
|
$1.78M |
Top Sells
| 1 |
COHR
Coherent Inc
COHR
|
$3.62M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$2.96M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$2.37M |
| 4 |
IDEAYA Biosciences
IDYA
|
$1.8M |
| 5 |
Dyne Therapeutics
DYN
|
$1.77M |
Sector Composition
| 1 | Healthcare | 46.35% |
| 2 | Technology | 22.42% |
| 3 | Financials | 15.33% |
| 4 | Communication Services | 4.08% |
| 5 | Consumer Discretionary | 3.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Fate Therapeutics
FATE
$120M
| $2.5M | 1.43% | 111,545 -7,233 | -6% | -$162K |
|
27
NovoCure
NVCR
$1.38B
| $2.13M | 1.22% | 28,007 | – | – |
|
28
Viridian Therapeutics
VRDN
$1.5B
| $2.1M | 1.2% | 102,372 +57,333 | +127% | +$1.18M |
|
|
CPARU
29
DELISTED
Catalyst Partners Acquisition Corp. Unit
CPARU
| $1.98M | 1.13% | 200,000 | – | – |
|
30
Arcus Biosciences
RCUS
$1.13B
| $1.87M | 1.07% | 71,650 | – | – |
|
31
Crinetics Pharmaceuticals
CRNX
$2.92B
| $1.81M | 1.03% | 92,047 +59,099 | +179% | +$1.16M |
|
|
32
Cogent Biosciences
COGT
$1.69B
| $1.78M | 1.01% | +118,935 | New | +$1.78M |
|
|
KDNY
33
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.64M | 0.94% | 83,551 +32,717 | +64% | +$643K |
|
34
Biomea Fusion
BMEA
$116M
| $1.42M | 0.81% | 144,727 | – | – |
|
|
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
| $1.38M | 0.79% | 395,332 | – | – |
|
36
Generation Bio
GBIO
$40.4M
| $1.32M | 0.76% | 248,994 | – | – |
|
|
37
Dyne Therapeutics
DYN
$1.92B
| $1.3M | 0.74% | 102,431 -139,436 | -58% | -$1.77M |
|
38
Gossamer Bio
GOSS
$562M
| $1.16M | 0.66% | 96,795 | – | – |
|
39
Relmada Therapeutics
RLMD
$37.2M
| $1.11M | 0.64% | 30,063 +570 | +2% | +$21.1K |
|
40
Cullinan Oncology
CGEM
$445M
| $1.03M | 0.59% | +79,918 | New | +$1.03M |
|
41
Edgewise Therapeutics
EWTX
$1.51B
| $1.02M | 0.58% | 103,462 | – | – |
|
42
Invesco DB Commodity Index Tracking Fund
DBC
$1.27B
| $1.01M | 0.58% | 42,396 | – | – |
|
43
Ascendis Pharma
ASND
$11.8B
| $1.01M | 0.58% | 9,780 +2,338 | +31% | +$241K |
|
44
AnaptysBio
ANAB
$569M
| $944K | 0.54% | 36,987 +3,884 | +12% | +$99.1K |
|
45
Microsoft
MSFT
$3.77T
| $929K | 0.53% | 3,988 | – | – |
|
46
Syndax Pharmaceuticals
SNDX
$1.41B
| $892K | 0.51% | +37,104 | New | +$892K |
|
47
Neurocrine Biosciences
NBIX
$13.8B
| $889K | 0.51% | 8,373 +4,606 | +122% | +$489K |
|
48
Sarepta Therapeutics
SRPT
$1.78B
| $885K | 0.51% | 8,009 -1,572 | -16% | -$174K |
|
49
Acadia Pharmaceuticals
ACAD
$4.38B
| $872K | 0.5% | 53,318 +13,418 | +34% | +$219K |
|
50
Alnylam Pharmaceuticals
ALNY
$58.5B
| $848K | 0.48% | 4,239 -749 | -15% | -$150K |
|